Algeria vs Pakistan: Average cost of multi drug-resistant tuberculosis treatment
Algeria
440 constant 2022 US$
in 2022
Pakistan
460 constant 2022 US$
in 2024
Algeria rank
85th
Pakistan rank
82nd
Average cost of multi drug-resistant tuberculosis treatment over time
- Algeria
- Pakistan
How they compare
Pakistan currently reports 460 constant 2022 US$ against 440 constant 2022 US$ in Algeria, a difference of 20 constant 2022 US$.
Across all 5 years both countries report, Pakistan has been ahead every year.
Algeria ranks 85th and Pakistan ranks 82nd of 92 countries.
Pakistan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Algeria | Pakistan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 862.5 constant 2022 US$ | 4,600 constant 2022 US$ | 3,738 constant 2022 US$ | Pakistan |
| 2020s | 680 constant 2022 US$ | 2,021 constant 2022 US$ | 1,341 constant 2022 US$ | Pakistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Algeria or Pakistan?
- Pakistan, at 460 constant 2022 US$ against 440 constant 2022 US$ in Algeria as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Algeria and Pakistan?
- 20 constant 2022 US$, with Pakistan ahead.
- How many years of comparable data are there for Algeria and Pakistan?
- 5 years are reported by both, from 2017 to 2022.
- How do Algeria and Pakistan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Algeria ranks 85th and Pakistan ranks 82nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.